• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Infectious Disease

Increase in Guillain-Barré syndrome linked to Zika virus outbreak in French Polynesia

byMelissa McCoyandStefan Trela
March 7, 2016
in Infectious Disease, Neurology, Public Health
Reading Time: 2 mins read
Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]
Share on FacebookShare on Twitter

 

1. This case-control study of a Zika virus outbreak in French Polynesia showed that an increased incidence of Guillain-Barré syndrome was associated with recent Zika virus infection.

2. History of past dengue virus infection did not significantly differ between cases and control groups as analyzed via retrospective serum immunoassays.

Evidence Rating Level: 3 (Average)

Study Rundown: During an outbreak of Zika virus between October 2013 and April 2014 in French Polynesia, there was also an increase in the incidence of Guillain-Barré syndrome, an autoimmune disease causing acute paralysis. This study sought to assess the role played by Zika virus and dengue virus infections as risk factors for the development of Guillain-Barré syndrome. Patients diagnosed with Guillain-Barré syndrome were matched with controls who presented with non-febrile illness (control group one), as well as patients with acute Zika virus disease but no neurological symptoms (control group two).

Virological investigations were performed to assess for past and current Zika and dengue virus infection in control groups one and two, respectively. 98% of patients diagnosed with Guillain-Barré syndrome demonstrated evidence of past or current Zika virus infection compared to 56% of patients in controls group one. History of dengue virus infection did not significantly differ between patients with Guillain-Barré syndrome and control groups one and two. Though this study provides the first evidence of Zika virus as a potential cause of Guillain-Barré syndrome, it was limited in that retrospective serum samples were unable to be tested for rising antibody titers to absolutely confirm recent Zika virus infection.

RELATED REPORTS

Center of Disease Control layoffs raise alarm over surveillance and preparedness

New York confirms first locally acquired chikungunya case in six years

Annexon Biosciences: ANX005 Antibody Shines in Phase 3 Trials For Treatment Of Guillain-Barré Syndrome

Click to read the study in The Lancet

Relevant Reading: Zika virus infection complicated by Guillain-Barre syndrome – case report, French Polynesia, December 2013

In-Depth [case-control study]: This case-control study investigated the role played by Zika virus and dengue virus infection as risk factors for Guillain-Barré syndrome. During a Zika virus outbreak in French Polynesia, patients with Guillain-Barré syndrome (cases) were sex-matched, age-matched, and residence matched to patients with non-febrile illness (control group one; n=98) as well as age-matched to patients with acute Zika virus disease but no neurological symptoms (control group two; n=70). Diagnosis of infection was done through the use of Zika virus-specific RT-PCR, and seroneutralization and microsphere immunofluoroescent assays for both Zika and dengue virus. In patients with Guillain-Barré syndrome, anti-glycolipid reactivity was analyzed via ELISA and combinatorial assays.

Of 42 patients with Guillain-Barré syndrome, 41 (98%) demonstrated anti-Zika IgM or IgG, and all had neutralizing antibodies against Zika virus as opposed to 54 (56%) of 98 in control group one (p<0.0001). Anti-glycolipid activity was demonstrated by ELISA in 13 (31%) patients and by glycoarray in 19 (46%) patients. Past history of dengue virus did not significantly differ between Guillain-Barré syndrome patients and those in control groups one and two (95%, 89%, and 83%, respectively.)

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Guillain-BarréZika
Previous Post

Nanobubble surgery could eliminate residual tumors and increase survival [PreClinical]

Next Post

High body fat percentage and low BMI independently associated with increased mortality

RelatedReports

Adding trained interventionists to primary care results in weight loss
All Specialties

Center of Disease Control layoffs raise alarm over surveillance and preparedness

September 4, 2026
Intrauterine Zika virus infection associated with significant fetal brain abnormalities
All Specialties

New York confirms first locally acquired chikungunya case in six years

September 4, 2026
Intrapartum antibiotics associated with altered infant gut microbiome
Pharma

Annexon Biosciences: ANX005 Antibody Shines in Phase 3 Trials For Treatment Of Guillain-Barré Syndrome

June 24, 2024
2 Minute Medicine Rewind January 28, 2019
Weekly Rewinds

2 Minute Medicine Rewind January 28, 2019

February 1, 2019
Next Post
Hormone levels independent of BMI with contraceptive implant

High body fat percentage and low BMI independently associated with increased mortality

Diet and physical activity promotion associated with decreased risk of type 2 diabetes

Low aerobic capacity and strength in youth associated with increased risk of diabetes in adulthood

Inhibition of apoliprotein lowers triglyceride levels

Naltrexone-bupropion may reduce adverse cardiovascular events in obese patients

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Historical redlining associated with lower breast cancer screening across urban neighborhoods
  • N-methylaniline exposure identified as likely cause of methemoglobinemia during maritime migration
  • Video mental health care may have clinical advantages versus phone or in-person visits
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.